Historic Time in Treatment of CF as Promising Drugs Reach Phase 3 Trials
Site Search
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
More than 4,600 cystic fibrosis researchers and health care professionals gathered Oct. 27 - 29 in Orlando for the 30th annual North American Cystic Fibrosis Conference. Recordings of the three plenary sessions are now available online.
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Medical Experts From 46 Countries to Collaborate at World's Largest Forum on CF Research and Care for Life-Threatening Genetic Disease